Skip to main content

Advertisement

Log in

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

The Global Anticoagulant Registry in the FIELDAtrial Fibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention in patients with non-valvular AF.

Methods and results

52,080 patients with newly diagnosed AF were prospectively enrolled from 2010 to 2016. 4121 (7.9%) of these patients were recruited in DACH [Germany (n = 3567), Austria (n = 465) and Switzerland (n = 89) combined], and 47,959 patients were from 32 countries in other regions worldwide (ORW). Hypertension was most prevalent in DACH and ORW (85.3% and 75.6%, respectively). Diabetes, hypercholesterolaemia, carotid occlusive disease and vascular disease were more prevalent in DACH patients vs ORW (27.6%, 49.4%, 5.8% and 29.0% vs 21.7%, 40.9%, 2.8% and 24.5%). The use of non-vitamin K antagonist oral anticoagulants (NOACs) increased more in DACH over time. Management of vitamin K antagonists was suboptimal in DACH and ORW (time in therapeutic range of INR ≥ 65% in 44.6% and 44.4% of patients or ≥ 70% in 36.9% and 36.0% of patients, respectively). Adjusted rates of cardiovascular mortality and MI/ACS were higher in DACH while non-haemorrhagic stroke/systemic embolism was lower after 2-year follow-up.

Conclusions

Similarities and dissimilarities in AF management and clinical outcomes are seen in DACH and ORW. The increased use of NOAC was associated with a mismatch of risk-adapted anticoagulation (over-and-undertreatment) in DACH. Suboptimal control of INR requires educational activities in both regional groups. Higher rates of cardiovascular death in DACH may reflect the higher risk profile of these patients and lower rates of non-haemorrhagic stroke could be associated with increased NOAC use.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

AP antiplatelet, DACH Germany Austria and Switzerland, ORW other regions worldwide, NOAC non-vitamin K oral anticoagulant, VKA Vitamin-K antagonist.

Fig. 2

AP antiplatelet, DACH Germany Austria and Switzerland, ORW other regions worldwide, NOAC non-vitamin K oral anticoagulant, VKA vitamin-K antagonist.

Fig. 3

AP antiplatelet, DACH Germany Austria and Switzerland, ORW other regions worldwide, NOAC non-vitamin K oral anticoagulant, VKA vitamin-K antagonist.

Fig. 4

ACS acute coronary syndrome, DACH Germany Austria and Switzerland, MI myocardial infarction, ORW other regions worldwide.

Similar content being viewed by others

References

  1. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6):1115–1119

    Article  PubMed  Google Scholar 

  2. Schnabel RBWS, Wild PS, Munzel T, Blankenberg S (2012) Atrial fibrillation—its prevalence and risk factor profile in the german general population. Dtsch Arztebl Int 109(16):293–299

    PubMed  PubMed Central  Google Scholar 

  3. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A et al (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34(35):2746–2751

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al (2014) A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16(3):308–319

    Article  PubMed  Google Scholar 

  5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    Article  CAS  PubMed  Google Scholar 

  6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus Warfarin in nonvalvular Atrial Fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992

    Article  CAS  PubMed  Google Scholar 

  8. Giugliano RP RC, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 369(22):2093–104

  9. Fox KAA, Gersh BJ, Traore S, Camm AJ, Kayani G, Krogh A et al (2017) Evolving quality standards for large-scale registries: the GARFIELD-AF experience. Eur Heart J Qual Care Clin Outcomes 3:114–122

    PubMed  Google Scholar 

  10. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E et al (2017) Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart (British Cardiac Society) 103(4):307–314

    PubMed  Google Scholar 

  11. K/DOQI clinical practice guidelines for chronic kidney disease (2002) evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-266

    Google Scholar 

  12. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S et al (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 163(1):13-9e1

    Article  PubMed  Google Scholar 

  13. Lip GY (2011) Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 124(2):111–114

    Article  PubMed  Google Scholar 

  14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093–1100

    Article  PubMed  Google Scholar 

  15. Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA et al (2017) Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 7(12):e017157

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236–239

    Article  CAS  PubMed  Google Scholar 

  17. Hohnloser SHBE, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol 108(9):1042–1052

    Article  CAS  PubMed  Google Scholar 

  18. Le Heuzey JY, Bassand JP, Berneau JB, Cozzolino P, D'Angiolella L, Doucet B et al (2018) Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. Arch Cardiovasc Dis

  19. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 14(10):1385–1413

    Article  PubMed  Google Scholar 

  20. Beinema M, Brouwers JR, Schalekamp T, Wilffert B (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100(6):1052–1057

    CAS  PubMed  Google Scholar 

  21. Excellence NioHaC. Quality standard [QS93] Atrial Fibrilation 2015

  22. Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ et al (2016) Quality of Vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS ONE 11(10):e0164076

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J

  24. Oh SGS, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK (2016) Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol 15(223):543–547

    Article  Google Scholar 

  25. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J et al (2014) Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 111(5):833–841

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank all physicians, nurses, and patients involved in the GARFIELD-AF registry worldwide. Editorial support was provided by Shakirah Chowdhury and programming support was provided by Madhusudana Rao (Thrombosis Research Institute, London, UK).

Funding

This work was supported by an unrestricted research grant from Bayer AG (Berlin, Germany) to the Thrombosis Research Institute (London, UK), which sponsors the GARFIELD-AF registry. The funding source had no involvement in the data collection, data analysis, or data interpretation.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Sylvia Haas.

Ethics declarations

Conflict of interest

Sylvia Haas: Honoraria from Bayer Pharma AG, Bristol Meyer Squibb, Daiichi-Sankyo, Pfizer and Sanofi. John Camm: institutional grants and personal fees from Bayer, Boehringer Ingelheim, Pfizer/BMS and Daiichi Sankyo, Anthos. Harald Darius: Speaker fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, DaiichiSankyo Consultancy fees from Boehringer Ingelheim. Jan Steffel: consultant and / or speaker fees from Abbott, Alexion, Amgen, Astra-Zeneca, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, BMS, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Organon, Pfizer, Saja, Servier, and WebMD. He reports ownership of CorXL. Sebastian Schellong: Speaker fees from Bayer Pharma AG, Boehringer-Ingelheim, Bristol Meyer Squibb, Daiichi-Sankyo, Sanofi Aventis and Pfizer. Consultancy fees from Bayer Pharma AG, Boehringer-Ingelheim, Daiichi-Sankyo, Sanofi Aventis, Aspen and Pfizer. Ajay K Kakkar; Frank Misselwitz; Gloria Kayani; Karen Pieper; Marianne Brodmann; Saverio Virdone: none.

Additional information

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.

A complete list of investigators is given in the online Appendix.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 kb)

Supplementary file2 (DOCX 60 kb)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haas, S., Camm, J.A., Harald, D. et al. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clin Res Cardiol 112, 759–771 (2023). https://doi.org/10.1007/s00392-022-02079-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-022-02079-y

Keywords

Navigation